CORRELATION OF INTERLEUKIN-6 (IL-6) LEVEL AND NUMBER OF LYMPHOCYTES IN COVID-19 POSITIVE PATIENTS AT PERSAHABATAN HOSPITAL
Article Sidebar
Main Article Content
Abstract
Covid-19 caused by the SARS-CoV-2 virus and is transmitted through droplets. In Covid-19 patients who are critical or have severe symptoms, hypercytokines are often found, which is characterized by an increase in the cytokine Interleukin-6 (IL-6). High levels of IL-6 cytokines can disrupt the immune system, including leukocytes, especially lymphocytes, which are the main system of the immune response. The state of continued inflammation and continuously stimulated lymphocytes will cause the lymphocytes to work too hard. This study aims to determine the relationship of Interleukin-6 (IL-6) with lymphocytes in Covid-19 positive patients. This study is a quantitative research with correlation analysis method using data collection technique by purposive sampling. Furthermore, to analyze, the authors used the Kolmogorov-Smirnov normality test and the Spearman correlation test. The results of the analysis showed a fairly significant correlation between levels of Interleukin-6 (IL-6) and the number of lymphocytes in Covid-19 positive patients.
Downloads
Article Details
Copyright (c) 2022 Dian Wijayanti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Li L quan, Huang T, Wang Y qing, Wang Z ping, Liang Y, Huang T bi, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–83.
Black J and LJB. Microbiology Principles and Explorations. 9th ed. Wiley; 2015.
Tortora, GJ; Funke, BR; Case C. Microbiology an Introduction. 12th ed. Pearson; 2020. 390–419 p.
Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. Molecular Sciences A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci [Internet]. 2020;2020:2657. Available from: www.mdpi.com/journal/ijms
Rothan HA, Byrareddy SN. Since January 2020 Elsevier has created a COVID-19 resource center with free information in English and Mandarin on the novel coronavirus COVID-19 . The COVID-19 resource center is hosted on Elsevier Connect, the company's public news and information. 2020;(January).
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382(13):1199–207.
World Health Organization. WHO announces COVID-19 outbreak a pandemicNo Title [Internet]. 2020. Available from: https://www.euro.who.int/en/health-topics/health- emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak -a-pandemic
Task Force for the Acceleration of Handling COVID-19. Distribution Map [Internet]. 2020. Available from: https://covid19.go.id/peta-sebaran
Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on the epi- demiological characteristics of novel coronavirus pneumonia (COVID-19). 2020;41(2):139–44.
Chousterman, BG; Filip, K; Georg F. Cytokine storm and sepsis disease pathogenesis. 2017;39(5):517–8.
Suxin, Wan; Qingjie, Yi; Shibing, Fan; Jinglong, Lv; Xianxiang, Zhang; Lian, Guo; Chunhui, Lang; Qing, Xiao; Kaihu, Xiao; Zhengjun, Yi; Mao, Qiang; Jianglin XBZY. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020;
Jones, Simon & Brendan J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;773–89.
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reducing mortality. Int J Antimicrobial Agents. 2020 May 1;55(5):105954.
Mueller YM, Katsikis PD, Bucks CM, Norton JA, Boesteanu AC. T Cell Exhaustion + Sufficient to Drive CD8 Chronic Antigen Stimulation Alone Is. J Immunol Ref [Internet]. 2009;182:6697–708. Available from: http://www.jimmunol.org/content/182/11/6697http://www.jimmunol.org/content/182/11/6697.full#ref-list-1
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID- 19. Am J Hematol. 2020;95(7):834–47.
Chiba, Yukino; Mizoguchi, Izuru, Hideaki, Hasegawa; Mio, Ohashi; Naoko, Orii; Taro, Nagai; Miyaka, Sugahara; Yasunori, Miyamoto; Mingli, Xu; Toshiyuki, Owaki; Takayuki Y. Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases. Cell Mol Life Sci. 2017;7.
Tan, L; Wang, Q; Zhang, D; Ding J. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther [Internet]. 2020;5(33). Available from: https://doi.org/10.1038/s41392-020-0148-4
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.
Yang B, Chang X, Huang J, Pan W, Si Z, Zhang C, et al. The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19. Int Immunopharmacol. 2021 Aug 1;97:107569.
Ho FK, Petermann-Rocha F, Gray SR, Jani BD, Vittal Katikireddi S, Niedzwiedz CL, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS One [Internet]. 2020;15(11 November):1–11. Available from: http://dx.doi.org/10.1371/journal.pone.0241824
Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021 May;97(1147):312-320. doi: 10.1136/postgradmedj-2020-138577. Epub 2020 Sep 25. PMID: 32978337.
Trougakos, I.P., Stamatelopoulos, K., Terpos, E. et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci 28, 9 (2021). https://doi.org/10.1186/s12929-020-00703-
Sari SD, Mawanti WT, Martalena D, Listiyaningsih E, Avissa R, Latifah R, Sukarya WS, Ikhsan MR, Pramono RB, Sinorita H, Susanti VY. Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels. J Med Sci. 2021 Jul;53(3):218-25.5
Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Internet]. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/